JP2020502135A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020502135A5 JP2020502135A5 JP2019531812A JP2019531812A JP2020502135A5 JP 2020502135 A5 JP2020502135 A5 JP 2020502135A5 JP 2019531812 A JP2019531812 A JP 2019531812A JP 2019531812 A JP2019531812 A JP 2019531812A JP 2020502135 A5 JP2020502135 A5 JP 2020502135A5
- Authority
- JP
- Japan
- Prior art keywords
- drugs
- plasminogen
- composition according
- drug
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016110169 | 2016-12-15 | ||
| CNPCT/CN2016/110169 | 2016-12-15 | ||
| CN2016110174 | 2016-12-15 | ||
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| PCT/CN2017/089059 WO2018107699A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗药物性肾损伤的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020502135A JP2020502135A (ja) | 2020-01-23 |
| JP2020502135A5 true JP2020502135A5 (https=) | 2020-07-30 |
| JP7242057B2 JP7242057B2 (ja) | 2023-03-20 |
Family
ID=62557856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531809A Active JP7182793B2 (ja) | 2016-12-15 | 2017-06-19 | 病理学的腎組織損傷を予防及び治療するための方法 |
| JP2019531812A Active JP7242057B2 (ja) | 2016-12-15 | 2017-06-19 | 薬物性腎損傷を予防及び治療するための方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531809A Active JP7182793B2 (ja) | 2016-12-15 | 2017-06-19 | 病理学的腎組織損傷を予防及び治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20190343930A1 (https=) |
| EP (2) | EP3556386A4 (https=) |
| JP (2) | JP7182793B2 (https=) |
| CN (2) | CN110167582A (https=) |
| CA (2) | CA3047171A1 (https=) |
| TW (4) | TW202123962A (https=) |
| WO (3) | WO2018107699A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11154595B2 (en) | 2016-12-15 | 2021-10-26 | Talengen International Limited | Method for preventing and treating pulmonary fibrosis |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CN113456579B (zh) * | 2021-07-12 | 2023-04-25 | 南开大学 | 具有双靶点的hdac抑制剂的纳米胶束-水凝胶制剂在治疗急性肾损伤药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| CN87104683A (zh) * | 1986-05-15 | 1988-12-21 | 埃默里大学 | 改善血纤维蛋白溶解作用的组合物 |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US7202066B2 (en) | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| AU2003210137A1 (en) * | 2002-02-06 | 2003-09-02 | N-Zyme Biotec Gmbh | Method for producing recombinant proteins in micro-organisms |
| EP1509236A4 (en) * | 2002-05-13 | 2008-07-30 | Children S Hospital Los Angele | TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS |
| BR0316583A (pt) * | 2002-12-10 | 2005-10-04 | Wyeth Corp | Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) |
| US20050250694A1 (en) * | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| JP2008510814A (ja) * | 2004-08-23 | 2008-04-10 | ワイス | Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸 |
| US8741260B2 (en) | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| AU2007290881B2 (en) * | 2006-08-28 | 2013-03-07 | Omnio Healer Ab | Candidates against infection |
| ES2516717T3 (es) * | 2009-05-26 | 2014-10-31 | Universidad De Salamanca | Proteína activadora de GM2 en orina como marcador de fallo renal agudo o de riesgo de desarrollar fallo renal agudo |
| WO2011004011A1 (en) * | 2009-07-10 | 2011-01-13 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| CN102121023B (zh) * | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| JP6085568B2 (ja) * | 2011-01-05 | 2017-02-22 | スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ | プラスミノーゲンおよびプラスミンの変異体 |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| AU2012315586B2 (en) * | 2011-09-29 | 2017-07-20 | Mayo Foundation For Medical Education And Research | Aromatic-cationic peptides and methods for using same |
| TN2016000048A1 (en) * | 2013-08-13 | 2017-07-05 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
| CA2939897A1 (en) * | 2014-02-21 | 2015-08-27 | Astellas Pharma Inc. | New anti-human pai-1 antibody |
-
2017
- 2017-06-19 EP EP17880935.6A patent/EP3556386A4/en active Pending
- 2017-06-19 CN CN201780078117.3A patent/CN110167582A/zh active Pending
- 2017-06-19 WO PCT/CN2017/089059 patent/WO2018107699A1/zh not_active Ceased
- 2017-06-19 TW TW110102361A patent/TW202123962A/zh unknown
- 2017-06-19 US US16/469,991 patent/US20190343930A1/en not_active Abandoned
- 2017-06-19 JP JP2019531809A patent/JP7182793B2/ja active Active
- 2017-06-19 JP JP2019531812A patent/JP7242057B2/ja active Active
- 2017-06-19 WO PCT/CN2017/089060 patent/WO2018107700A1/zh not_active Ceased
- 2017-06-19 CA CA3047171A patent/CA3047171A1/en not_active Abandoned
- 2017-06-19 CA CA3047170A patent/CA3047170A1/en not_active Abandoned
- 2017-06-19 US US16/469,960 patent/US20190328848A1/en not_active Abandoned
- 2017-06-19 TW TW106120455A patent/TW201822797A/zh unknown
- 2017-06-19 EP EP17881449.7A patent/EP3556388A4/en active Pending
- 2017-06-19 WO PCT/CN2017/089055 patent/WO2018107695A1/zh not_active Ceased
- 2017-06-19 CN CN201780078167.1A patent/CN110366427A/zh active Pending
- 2017-06-20 TW TW106120521A patent/TWI642441B/zh active
- 2017-06-20 TW TW106120523A patent/TWI661838B/zh active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020502135A5 (https=) | ||
| Yu et al. | Expert consensus on the use of human serum albumin in critically ill patients | |
| Mohammed et al. | Contrast-induced nephropathy | |
| Banerjee et al. | Management of heart failure patient with CKD | |
| Priante et al. | Cell death in the kidney | |
| Finkel et al. | THE CLINICAL APPLICATION OF CRRT—CURRENT STATUS: Complications of Continuous Renal Replacement Therapy | |
| Rabe et al. | Non-transgenic mouse models of kidney disease | |
| Chiurchiu et al. | Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses | |
| Rodríguez‐Romo et al. | Epigenetic regulation in the acute kidney injury to chronic kidney disease transition | |
| Dell’anna et al. | Early neuroprotection after cardiac arrest | |
| JP2020502155A5 (https=) | ||
| Iqbal et al. | Diuretic resistance and its management | |
| JP2020502134A5 (https=) | ||
| Ponticelli et al. | Renin-angiotensin system inhibitors in kidney transplantation: a benefit-risk assessment | |
| Baldwin et al. | Treatment of hypertension in renal disease | |
| CN110167582A (zh) | 一种预防和治疗药物性肾损伤的方法 | |
| Kaldre et al. | Optimization of histone deacetylase inhibitor activity in non-secosteroidal vitamin D-receptor agonist hybrids | |
| Bassand | Novel oral anticoagulants in acute coronary syndrome: re-evaluating the thrombin hypothesis | |
| Palmer et al. | Renal considerations in the treatment of hypertension | |
| Nieto-Ríos et al. | Nephrotic syndrome as a manifestation of thrombotic microangiopathy due to long-term use of sunitinib | |
| Ogawa et al. | Urgent statement on antithrombotic therapy of atrial fibrillation | |
| Ohya et al. | A new xanthine oxidase inhibitor: the uric acid reduction and additional efficacy in CKD patients | |
| Sever et al. | CD2AP, dendrin, and cathepsin L in the kidney | |
| Rosner et al. | Drug-associated acute kidney injury in the intensive care unit | |
| Walker et al. | Chronic interstitial nephritis |